Buprenorphine pharmacotherapy and behavioral treatment: Comparison of outcomes among prescription opioid users, heroin users and combination users

Journal of Substance Abuse Treatment

Volumn 48, Issue 1, 2015, Pages 70-76

  Nielsen, Suzanne ^a   Hillhouse, Maureen ^b   Mooney, Larissa ^b   Ang, Alfonso ^b   Ling, Walter ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Prescription opioid; Treatment

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; OPIATE; PRESCRIPTION DRUG; BUPRENORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT;

ADDICTION SEVERITY INDEX; ADULT; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DSM-IV; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; MENTAL HEALTH; MORPHINE ADDICTION; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SELF HELP; SHORT FORM 36; TREATMENT DURATION; TREATMENT EFFECTIVENESS SCORE; UNSPECIFIED SIDE EFFECT; BEHAVIOR THERAPY; COMPARATIVE STUDY; DRUG MISUSE; HEROIN DEPENDENCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANALGESICS, OPIOID; BEHAVIOR THERAPY; BUPRENORPHINE; BUPRENORPHINE, NALOXONE DRUG COMBINATION; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; NALOXONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE; TREATMENT OUTCOME;

EID: 84922912406     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.06.006     Document Type: Article

References (32)

1. Amass L., Kamien J.B., Mikulich S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence 2000, 58(1-2):143-152.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders (4th ed., text rev.) 2000, (Washington DC).
3. Brands B., Blake J., Sproule B., Gourlay D., Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug and Alcohol Dependence 2004, 73(2):199-207.
4. Brewer D.D., Catalano R.F., Haggerty K., Gainey R.R., Fleming C.B. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998, 93(1):73-92.
5. Caplehorn J.R., Drummer O.H. Fatal methadone toxicity: Signs and circumstances, and the role of benzodiazepines. Australian and New Zealand Journal of Public Health 2002, 26(4):358-362.
6. Childress A.R., McLellan A.T., O'Brien C.P. Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. British Journal of Addiction 1986, 81(5):655-660.
7. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug and Alcohol Dependence 2006, 81(2):103-107.
8. Fischer B., Nakamura N., Rush B., Rehm Jürgen, Urbanoski K. Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004-2009. Drug and Alcohol Dependence 2010, 109:257-260.
9. Fischer B., Patra J., Cruz M.F., Gittins J., Rehm J. Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug and Alcohol Review 2008, 27(6):625-632.
10. Heinrich C.J., Fournier E. Instruments of policy and administration for improving substance abuse treatment practice and program outcomes. Journal of Drug Issues 2005, 35(3):485-505.
11. Ling W., Hillhouse M., Ang A., Jenkins J., Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction 2013, 108:1788-1798.
12. Ling W., Hillhouse M., Domier C., Doraimani G., Hunter J., Thomas C., et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009, 104(2):256-265.
13. Ling W., Shoptaw S., Wesson D., Rawson R.A., Compton M., Klett C.J. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Research Monograph 1997, 175:208-220.
14. Ling W., Wesson D.R. Clinical efficacy of buprenorphine: Comparisons to methadone and placebo. Drug and Alcohol Dependence 2003, 70(2 Suppl.):S49-S57.
15. Ling W., Wesson D.R., Charuvastra C., Klett C.J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry 1996, 53(5):401-407.
16. Lintzeris N., Nielsen S. Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. The American Journal on Addictions 2010, 19(1):59-72.
17. Little R.J., Ruben D.B. Statistical analysis with missing data 2002, (New Yotk). 2nd ed.
18. Magura S., Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mount Sinai Journal of Medicine 2001, 68(1):62-74.
19. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, 16(2):CD002207.
20. Maxwell J.C. The prescription drug epidemic in the United States: A perfect storm. Drug and Alcohol Review 2011, 30(3):264-270. 10.1111/j.1465-3362.2011.00291.x.
21. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992, 9(3):199-213.
22. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., et al. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. Journal of General Internal Medicine 2007, 22(4):527-530.
23. Nielsen S., Dietze P., Lee N., Dunlop A., Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007, 102(4):616-622.
24. Nielsen S., Hillhouse M., Mooney L., Fahey J., Ling W. Comparing buprenorphine induction experience with heroin and prescription opioid users. Journal of Substance Abuse Treatment 2012, 43(3):285-290.
25. Nielsen S., Hillhouse M., Thomas C., Hasson A., Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. Journal of Addiction Medicine 2013, 7(1):33-38.
26. Paulozzi L.J. Prescription drug overdoses: A review. Journal of Safety Research 2012, 43(4):283-289.
27. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics 1994, 55(5):569-580.
28. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992, 30(6):473-483.
29. Warner M., Chen L.H., Makuc D.M. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief 2009, Vol. 22:1-8. (Hyattsville, Maryland: Centers for Disease Control and Prevention National Center for Health Statistics, (O. o. A. a. Epidemiology, Trans.)).
30. Weiss R.D., Potter J.S., Fiellin D., Byrne M., Connery H.S., Dickinson W., et al. A two-phase randomized controlled trial of adjunctive counseling during brief and extended buprenorphine-naloxone treatment for presciption opioid dependence. Archives of General Psychiatry 2011, 68(12):1238-1246.
31. Wesson D.R., Ling W. The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 2003, 35(2):253-259.
32. Wu L.T., Woody G.E., Yang C., Blazer D.G. Subtypes of nonmedical opioid users: Results from the national epidemiologic survey on alcohol and related conditions. Drug and Alcohol Dependence 2010, 112(1-2):69-80.